[HTML][HTML] Epidemiology of pancreatic cancer: global trends, etiology and risk factors
Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide.
However, its toll is higher in more developed countries. Reasons for vast differences in …
However, its toll is higher in more developed countries. Reasons for vast differences in …
[HTML][HTML] Epidemiology of pancreatic cancer
Cancer of the pancreas remains one of the deadliest cancer types. Based on the
GLOBOCAN 2012 estimates, pancreatic cancer causes more than 331000 deaths per year …
GLOBOCAN 2012 estimates, pancreatic cancer causes more than 331000 deaths per year …
Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial
EM O'Reilly, DY Oh, N Dhani, DJ Renouf… - JAMA …, 2019 - jamanetwork.com
Importance New therapeutic options for patients with metastatic pancreatic ductal
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …
[HTML][HTML] Matrix stiffness induces epithelial–mesenchymal transition and promotes chemoresistance in pancreatic cancer cells
Increased matrix rigidity associated with the fibrotic reaction is documented to stimulate
intracellular signalling pathways that promote cancer cell survival and tumour growth …
intracellular signalling pathways that promote cancer cell survival and tumour growth …
[HTML][HTML] Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features
E Karamitopoulou - British journal of cancer, 2019 - nature.com
Pancreatic cancer is a lethal disease, with fewer than 7% of patients surviving beyond 5
years following diagnosis. Immune responses are known to influence tumour progression …
years following diagnosis. Immune responses are known to influence tumour progression …
[HTML][HTML] Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
SK Daniel, KM Sullivan, KP Labadie… - Clinical and translational …, 2019 - Springer
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with limited response to
cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor …
cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor …
[HTML][HTML] Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy?
I Belhabib, S Zaghdoudi, C Lac, C Bousquet, C Jean - Cancers, 2021 - mdpi.com
Simple Summary Stroma modifications observed in solid cancer are now recognized as
critical events for cancer progression and as potential therapeutic or diagnostic targets. The …
critical events for cancer progression and as potential therapeutic or diagnostic targets. The …
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
S Yu, C Zhang, KP Xie - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2021 - Elsevier
Pancreatic cancer is a lethal disease with limited opportunity for resectable surgery as the
first choice for cure due to its late diagnosis and early metastasis. The desmoplastic stroma …
first choice for cure due to its late diagnosis and early metastasis. The desmoplastic stroma …
[HTML][HTML] Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial
Y Liu, Y Guo, Z Wu, K Feng, C Tong, Y Wang, H Dai… - Cytotherapy, 2020 - Elsevier
The current clinical outcome for patients with metastatic pancreatic carcinoma (PC) remains
poor. Epidermal growth factor receptor (EGFR) is detectable in PC, suggesting that EGFR is …
poor. Epidermal growth factor receptor (EGFR) is detectable in PC, suggesting that EGFR is …
Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance
M Wartenberg, S Cibin, I Zlobec, E Vassella… - Clinical cancer …, 2018 - AACR
Purpose: Current clinical classification of pancreatic ductal adenocarcinoma (PDAC) is
unable to predict prognosis or response to chemo-or immunotherapy and does not take into …
unable to predict prognosis or response to chemo-or immunotherapy and does not take into …